These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

105 related items for PubMed ID: 20622200

  • 1. Tecarfarin, a novel vitamin K reductase antagonist, is not affected by CYP2C9 and CYP3A4 inhibition following concomitant administration of fluconazole in healthy participants.
    Bavisotto LM, Ellis DJ, Milner PG, Combs DL, Irwin I, Canafax DM.
    J Clin Pharmacol; 2011 Apr; 51(4):561-74. PubMed ID: 20622200
    [Abstract] [Full Text] [Related]

  • 2. Effect of tecarfarin, a novel vitamin K epoxide reductase inhibitor, on coagulation in beagle dogs.
    Choppin A, Irwin I, Lach L, McDonald MG, Rettie AE, Shao L, Becker C, Palme MP, Paliard X, Bowersox S, Dennis DM, Druzgala P.
    Br J Pharmacol; 2009 Nov; 158(6):1536-47. PubMed ID: 19845677
    [Abstract] [Full Text] [Related]

  • 3. Pharmacokinetics of Tecarfarin and Warfarin in Patients with Severe Chronic Kidney Disease.
    Albrecht D, Turakhia MP, Ries D, Marbury T, Smith W, Dillon D, Milner PG, Midei MG.
    Thromb Haemost; 2017 Nov; 117(11):2026-2033. PubMed ID: 28933798
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. A randomised, double blind comparison of tecarfarin, a novel vitamin K antagonist, with warfarin. The EmbraceAC Trial.
    Whitlock RP, Fordyce CB, Midei MG, Ellis D, Garcia D, Weitz JI, Canafax DM, Albrecht D, Milner PG.
    Thromb Haemost; 2016 Aug 01; 116(2):241-50. PubMed ID: 27173100
    [Abstract] [Full Text] [Related]

  • 6. The first evaluation of a novel vitamin K antagonist, tecarfarin (ATI-5923), in patients with atrial fibrillation.
    Ellis DJ, Usman MH, Milner PG, Canafax DM, Ezekowitz MD.
    Circulation; 2009 Sep 22; 120(12):1029-35, 2 p following 1035. PubMed ID: 19738136
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Fluconazole but not the CYP3A4 inhibitor, itraconazole, increases zafirlukast plasma concentrations.
    Karonen T, Laitila J, Niemi M, Neuvonen PJ, Backman JT.
    Eur J Clin Pharmacol; 2012 May 22; 68(5):681-8. PubMed ID: 22108774
    [Abstract] [Full Text] [Related]

  • 9. Time-dependent inhibition (TDI) of CYP3A4 and CYP2C9 by noscapine potentially explains clinical noscapine-warfarin interaction.
    Fang ZZ, Zhang YY, Ge GB, Huo H, Liang SC, Yang L.
    Br J Clin Pharmacol; 2010 Feb 22; 69(2):193-9. PubMed ID: 20233183
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Comparative pharmacokinetics of vitamin K antagonists: warfarin, phenprocoumon and acenocoumarol.
    Ufer M.
    Clin Pharmacokinet; 2005 Feb 22; 44(12):1227-46. PubMed ID: 16372822
    [Abstract] [Full Text] [Related]

  • 17. Differential genotype dependent inhibition of CYP2C9 in humans.
    Kumar V, Brundage RC, Oetting WS, Leppik IE, Tracy TS.
    Drug Metab Dispos; 2008 Jul 22; 36(7):1242-8. PubMed ID: 18378563
    [Abstract] [Full Text] [Related]

  • 18. Voriconazole and fluconazole increase the exposure to oral diazepam.
    Saari TI, Laine K, Bertilsson L, Neuvonen PJ, Olkkola KT.
    Eur J Clin Pharmacol; 2007 Oct 22; 63(10):941-9. PubMed ID: 17676319
    [Abstract] [Full Text] [Related]

  • 19. Safety and Tolerability of Tecarfarin (ATI-5923) in Healthy Chinese Volunteers: Multiple Oral Dose-Escalation Phase I Trial.
    Zhou Q, Wang Z, Wang H, Chen Z, Li X, Dai X, Zhang Y, Yu X, Zhou R, Hu W.
    Am J Cardiovasc Drugs; 2023 Jan 22; 23(1):101-112. PubMed ID: 36622539
    [Abstract] [Full Text] [Related]

  • 20. Warfarin-fluconazole. III. A rational approach to management of a metabolically based drug interaction.
    Kunze KL, Trager WF.
    Drug Metab Dispos; 1996 Apr 22; 24(4):429-35. PubMed ID: 8801058
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.